Spectrum Health General Surgery Residency, Grand Rapids, MI; Department of Surgery, Michigan State University College of Human Medicine, Grand Rapids, MI.
Department of Surgery, Michigan State University College of Human Medicine, Grand Rapids, MI.
Surgery. 2021 Mar;169(3):649-654. doi: 10.1016/j.surg.2020.06.042. Epub 2020 Aug 15.
Pancreatic ductal adenocarcinoma has a high rate of recurrence after resection. We aimed to investigate patterns of recurrence of pancreatic ductal adenocarcinoma to identify opportunities for targeted intervention toward improving survival.
This was a retrospective analysis of consecutive patients that underwent curative-intent resection for pancreatic ductal adenocarcinoma between 2007 and 2015. Recurrence and survival were analyzed based on site of recurrence. Multiple clinicopathologic factors were calculated for likelihood of site-specific recurrence.
The study included 221 patients with median follow-up of 83 months. Median overall and recurrence-free survival was 19 and 13 months, respectively. Recurrence was observed in 71.9% patients. Local recurrence occurred in 16.4%, distant recurrence in 67.3%, and combined in 15.9%. The most common site of distant recurrence was the liver (49.7%) followed by lung (31.8%) and peritoneum (16.6%). Median time to liver recurrence was shortest (5 months, 95% confidence interval 1.7-8.3) and post recurrence survival was poor (4 months, 95% confidence interval 1.9-6.1). Patients with poorly differentiated tumors on pathology were 4.8 times more likely to recur in the liver (odds ratio 4.83, 95% confidence interval 1.7-13.9).
Liver metastasis after resection of pancreatic ductal adenocarcinoma occurs most frequently, earliest after surgery, and is rapidly fatal. Liver-directed therapies represent a target for future study.
胰腺导管腺癌在切除后复发率很高。我们旨在研究胰腺导管腺癌的复发模式,以确定改善生存的靶向干预机会。
这是一项回顾性分析,纳入了 2007 年至 2015 年间接受根治性切除的胰腺导管腺癌连续患者。根据复发部位分析复发和生存情况。计算了多种临床病理因素,以确定特定部位复发的可能性。
本研究纳入了 221 例患者,中位随访时间为 83 个月。中位总生存期和无复发生存期分别为 19 个月和 13 个月。71.9%的患者出现复发。局部复发 16.4%,远处复发 67.3%,两者合并 15.9%。远处复发最常见的部位是肝脏(49.7%),其次是肺(31.8%)和腹膜(16.6%)。肝转移的中位时间最短(5 个月,95%置信区间 1.7-8.3),且复发后生存较差(4 个月,95%置信区间 1.9-6.1)。病理上分化差的肿瘤患者肝转移的可能性高 4.8 倍(优势比 4.83,95%置信区间 1.7-13.9)。
胰腺导管腺癌切除后肝转移最常见,术后最早发生,且迅速致命。肝定向治疗代表了未来研究的目标。